Cetuximab-induced skin exanthema: prophylactic and reactive skin therapy are equally effective

PURPOSE: Treatment with cetuximab is accompanied by the development of an acneiform follicular skin exanthema in more than 80 % of patients. Severe exanthema (grade III/IV) develops in about 9–19 % of patients with the necessity of cetuximab dose reduction or cessation. METHODS: The study presented...

Descripción completa

Detalles Bibliográficos
Autores principales: Wehler, Thomas C., Graf, Claudine, Möhler, Markus, Herzog, Jutta, Berger, Martin R., Gockel, Ines, Lang, Hauke, Theobald, Matthias, Galle, Peter R., Schimanski, Carl C.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Springer Berlin Heidelberg 2013
Materias:
Original Paper
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3771414/
https://www.ncbi.nlm.nih.gov/pubmed/23918349
http://dx.doi.org/10.1007/s00432-013-1483-4

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3771414/
https://www.ncbi.nlm.nih.gov/pubmed/23918349
http://dx.doi.org/10.1007/s00432-013-1483-4

Ejemplares similares